US OptionsDetailed Quotes

SGMO241220C3000

Watchlist

0.10
-0.05-33.33%

15min DelayClose Dec 3 16:00 ET

0.14High0.05Low

Sangamo Therapeutics Stock Discussion

kingwang123

11 hours ago

$Sangamo Therapeutics (SGMO.US)$ come on u are better than this

Justin Teeburd

20 hours ago

Dipping day

$Sangamo Therapeutics (SGMO.US)$

72142214

Nov 26 09:18

$Sangamo Therapeutics (SGMO.US)$ watch this today

Andy-Lai

Nov 20 07:25

🥺❤️🔥🚀

$Sangamo Therapeutics (SGMO.US)$

Stock_Drift

Nov 20 04:42

Premarket Ticks are Lit. 5:40am 11/20/24

$Rumble (RUM.US)$ $Red Cat Holdings (RCAT.US)$ $Microvision (MVIS.US)$ $Bit Digital (BTBT.US)$ $Wix.com (WIX.US)$ $Sangamo Therapeutics (SGMO.US)$ $Above Food Ingredients (ABVE.US)$ $Exicure (XCUR.US)$ $Hoth Therapeutics (HOTH.US)$ $Kingsoft Cloud (KC.US)$ $Digital Brands Group (DBGI.US)$ $Tevogen Bio Holdings (TVGN.US)$ $Nauticus Robotics (KITT.US)$ $Tonix Pharmaceuticals (TNXP.US)$
📊⚡️📊

Andy-Lai

Nov 20 04:31

🔥🚀❤️

$Sangamo Therapeutics (SGMO.US)$

Jaguar8

Nov 19 19:33

One of my watchlist tomorrow. Why? FDA clearance of IND app for neuropathy

$Sangamo Therapeutics (SGMO.US)$

Stock_Drift

Nov 19 17:28

After Hours Ticks. 6:26pm

$Fresh2 (FRES.US)$ $Opus Genetics (IRD.US)$ $Sangamo Therapeutics (SGMO.US)$ $Kindly MD (KDLY.US)$ $Edesa Biotech (EDSA.US)$ $Sadot (SDOT.US)$ $Lazydays (GORV.US)$ $Zeo Energy (ZEO.US)$ $Hall Of Fame Resort & Entertainment (HOFV.US)$ $Nauticus Robotics (KITT.US)$ $KORE Group (KORE.US)$ $Digital Brands Group (DBGI.US)$ $Hoth Therapeutics (HOTH.US)$ $Tonix Pharmaceuticals (TNXP.US)$
📊⚡️📊

Trytosaveabit

Nov 19 15:20

News

$Sangamo Therapeutics (SGMO.US)$ Sangamo Therapeutics Gets FDA Clearance Of IND Application For ST-503 For Treatment Of Idiopathic Small Fiber Neuropathy
Benzinga· 3 mins ago

Jaguar8

Nov 19 15:16

NEWS

$Sangamo Therapeutics (SGMO.US)$
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Sangamo plans to initiate enrollment of patients in thePhase 1/2 study for ST-503 in mid-2025
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for i...

No comment yet